{"id":"W2604445332","doi":"10.1200/jco.2013.31.15_suppl.tps4157","title":"INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital","funders":"","keywords":"Medicine; Regorafenib; Clinical endpoint; Internal medicine; Bevacizumab; Placebo; Oncology; Phases of clinical research; Surrogate endpoint; Adverse effect; Ramucirumab; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02407323,0.0004246754,0.008230535,0.0005973965,0.00008885116,0.00003536317,0.0005542504,0.0002021215,0.0008137159],"category_scores_gemma":[0.01359705,0.0002207456,0.001299626,0.0006548827,0.0003380632,0.0003040433,0.0001454473,0.002054377,0.00000584704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003387575,"about_ca_system_score_gemma":0.0009783228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001046387,"about_ca_topic_score_gemma":0.0008851605,"domain_scores_codex":[0.9846448,0.004679421,0.008805807,0.0004372641,0.0009304704,0.0005022932],"domain_scores_gemma":[0.9786136,0.01193162,0.00789379,0.0004532762,0.0007122574,0.0003955241],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8691029,0.02872824,0.029707,0.00002147704,0.001842376,0.000340659,0.0007220631,0.00006477616,0.0001324883,0.000007075081,0.004936273,0.06439465],"study_design_scores_gemma":[0.902218,0.07140397,0.01299032,0.0001598543,0.003137908,0.00008284473,0.008911525,0.0001499182,0.00000717483,0.00004165947,0.0007660689,0.0001307254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818575,0.0006480466,0.0001371606,0.005036985,0.001180546,0.01067259,0.000003539326,0.00001491926,0.0004487193],"genre_scores_gemma":[0.9959981,0.0002944687,0.0005511069,0.00034809,0.0007805981,0.0005016312,0.000003439041,0.00003099973,0.001491557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06426393,"threshold_uncertainty_score":0.9947118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1461416750695312,"score_gpt":0.4933522990577978,"score_spread":0.3472106239882666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}